Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

RANKL synthesized by both stromal cells and cancer cells plays a crucial role in osteoclastic bone resorption induced by oral cancer.

Sato K, Lee JW, Sakamoto K, Iimura T, Kayamori K, Yasuda H, Shindoh M, Ito M, Omura K, Yamaguchi A.

Am J Pathol. 2013 May;182(5):1890-9. doi: 10.1016/j.ajpath.2013.01.038. Epub 2013 Mar 15.

2.

CXCL2 synthesized by oral squamous cell carcinoma is involved in cancer-associated bone destruction.

Oue E, Lee JW, Sakamoto K, Iimura T, Aoki K, Kayamori K, Michi Y, Yamashiro M, Harada K, Amagasa T, Yamaguchi A.

Biochem Biophys Res Commun. 2012 Aug 3;424(3):456-61. doi: 10.1016/j.bbrc.2012.06.132. Epub 2012 Jul 4.

PMID:
22771802
3.

Transforming growth factor-β synthesized by stromal cells and cancer cells participates in bone resorption induced by oral squamous cell carcinoma.

Nakamura R, Kayamori K, Oue E, Sakamoto K, Harada K, Yamaguchi A.

Biochem Biophys Res Commun. 2015 Mar 20;458(4):777-82. doi: 10.1016/j.bbrc.2015.02.013. Epub 2015 Feb 12.

PMID:
25681764
5.

The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.

Peng S, Liu XS, Huang S, Li Z, Pan H, Zhen W, Luk KD, Guo XE, Lu WW.

Bone. 2011 Dec;49(6):1290-8. doi: 10.1016/j.bone.2011.08.031. Epub 2011 Sep 9.

PMID:
21925296
6.
7.

Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.

Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.

Biochem Pharmacol. 2013 Sep 15;86(6):782-90. doi: 10.1016/j.bcp.2013.07.015. Epub 2013 Aug 6.

PMID:
23928189
8.

Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.

Lee JW, Iwahashi A, Hasegawa S, Yonezawa T, Jeon WB, Cha BY, Nagai K, Woo JT.

J Nat Med. 2012 Jan;66(1):8-16. doi: 10.1007/s11418-011-0537-7. Epub 2011 Jun 9.

PMID:
21656335
9.
10.

Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.

Mancino AT, Klimberg VS, Yamamoto M, Manolagas SC, Abe E.

J Surg Res. 2001 Sep;100(1):18-24.

PMID:
11516200
11.

Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption.

Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD, Zhang J.

Cancer Res. 2007 Apr 15;67(8):3646-53.

12.

Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.

Itoh K, Udagawa N, Matsuzaki K, Takami M, Amano H, Shinki T, Ueno Y, Takahashi N, Suda T.

J Bone Miner Res. 2000 Sep;15(9):1766-75.

13.

Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells.

Kayamori K, Sakamoto K, Nakashima T, Takayanagi H, Morita K, Omura K, Nguyen ST, Miki Y, Iimura T, Himeno A, Akashi T, Yamada-Okabe H, Ogata E, Yamaguchi A.

Am J Pathol. 2010 Feb;176(2):968-80. doi: 10.2353/ajpath.2010.090299. Epub 2009 Dec 24.

14.

Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.

Irie A, Takami M, Kubo H, Sekino-Suzuki N, Kasahara K, Sanai Y.

Bone. 2007 Aug;41(2):165-74. Epub 2007 May 5.

PMID:
17560185
15.

Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts.

Jun AY, Kim HJ, Park KK, Son KH, Lee DH, Woo MH, Chung WY.

Invest New Drugs. 2014 Feb;32(1):1-13. doi: 10.1007/s10637-013-9969-0. Epub 2013 May 15.

PMID:
23673814
16.

Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.

Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP.

J Bone Miner Res. 2005 Sep;20(9):1659-68. Epub 2005 May 2.

17.

P38 mitogen-activated protein kinase inhibitor, FR167653, inhibits parathyroid hormone related protein-induced osteoclastogenesis and bone resorption.

Tao H, Okamoto M, Nishikawa M, Yoshikawa H, Myoui A.

PLoS One. 2011;6(8):e23199. doi: 10.1371/journal.pone.0023199. Epub 2011 Aug 23.

18.

Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways.

Tsubaki M, Kato C, Manno M, Ogaki M, Satou T, Itoh T, Kusunoki T, Tanimori Y, Fujiwara K, Matsuoka H, Nishida S.

Mol Cell Biochem. 2007 Oct;304(1-2):53-60. Epub 2007 Jun 5.

PMID:
17549607
19.

Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.

Nishida S, Tsubaki M, Hoshino M, Namimatsu A, Uji H, Yoshioka S, Tanimori Y, Yanae M, Iwaki M, Irimajiri K.

Biochem Biophys Res Commun. 2005 Mar 4;328(1):91-7.

PMID:
15670755
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk